Platelet count-agnostic methods of treating myelofibrosis
Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy. Accordingly, methods of treating myeloproliferative neoplasms (MPN) such as myelofibrosis are described. The methods can include administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to a subject identified as having (i) myelofibrosis and (ii) a platelet count of less than 150×10 9 /L. Also described are methods including administering to a subject with myelofibrosis a therapeutically effective stable dose of momelotinib or a pharmaceutically acceptable salt thereof, for a period of a plurality of weeks, where the subject is assessed as maintaining a platelet count above a predetermined threshold platelet count during the period.
1 . A method of treating myelofibrosis in a subject, the method comprising: administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to a subject identified as having (i) myelofibrosis and (ii) a baseline platelet count of at least 100×10 9 /L but less than 150×10 9 /L, wherein the subject has previously been treated with a JAK inhibitor.
2 . The method of claim 1 , wherein the platelet count is a baseline platelet count determined within one week prior to initiation of momelotinib therapy, wherein the subject had not been treated with previous JAK inhibitor therapy for at least 2 weeks prior to momelotinib therapy.
3 . The method of claim 1 , wherein the subject has previously been treated with ruxolitinib.
4 . The method of claim 3 , wherein the subject is an adult human who has had an inadequate response to or is intolerant of ruxolitinib, or wherein the subject failed to respond or ceased to respond to previous ruxolitinib therapy.
5 . The method of claim 1 , wherein the subject has previously been treated with fedratinib.
6 . The method of claim 5 , wherein the subject is an adult human who has had an inadequate response to or is intolerant of fedratinib, or wherein the subject failed to respond or ceased to respond to previous fedratinib therapy.
7 . The method of claim 1 , wherein the myelofibrosis is intermediate or high-risk myelofibrosis.
8 . The method of claim 1 , wherein the myelofibrosis is primary myelofibrosis (PMF).
9 . The method of claim 1 , wherein the myelofibrosis is post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF).
10 . The method of claim 1 , wherein the momelotinib or the pharmaceutically acceptable salt thereof is momelotinib dihydrochloride salt.
11 . The method of claim 10 , wherein the momelotinib or the pharmaceutically acceptable salt thereof is momelotinib dihydrochloride monohydrate.
12 . The method of claim 11 , wherein the momelotinib or the pharmaceutically acceptable salt thereof is momelotinib dihydrochloride monohydrate Form II.
13 . The method of claim 1 , wherein the momelotinib or the pharmaceutically acceptable salt thereof is administered orally.
14 . The method of claim 1 , wherein the momelotinib or the pharmaceutically acceptable salt thereof is administered daily.
15 . The method of claim 14 , wherein the momelotinib or the pharmaceutically acceptable salt thereof is administered once daily.
16 . The method of claim 1 , wherein the therapeutically effective amount is between 50 mg/day and 200 mg/day.
17 . The method of claim 16 , wherein the therapeutically effective amount is 200, 150, or 100 mg/day.